抗病毒治疗乙型肝炎肝硬化伴肝源性糖尿病的临床疗效观察

目的探讨抗病毒治疗乙型肝炎肝硬化伴肝源性糖尿病的临床疗效。方法选取本院2007年1月～2011年10月50例乙型肝炎肝硬化伴肝源性糖尿病患者随机分为两组,对照组25例采用双环醇片（75～150mg/d,连用24周）联合熊去氧胆酸胶囊（250mg/d,连用24周）治疗,观察组25例在对照组用药基础上联合阿德福韦酯（10mg/d,连用24周）治疗,检测患者各项指标进行比较分析。结果观察组总有效率和HBV-DNA转阴情况均明显好于对照组,观察组肝功能指标ALT、AST、ALB和TBIL恢复状况明显好于对照组,观察组血糖指标FPG和2hPG明显好于对照组,差异有统计学意义（P〈0.05）。结论抗病毒治疗乙型肝炎肝硬化伴肝源性糖尿病的临床疗效显著,是一种安全有效的治疗手段,值得临床推广使用。

Clinical research on antiviral therapy in the treatment of hepatitis B cirrhosis with hepatic diabetes

Objective To investigate clinical efficacy on antiviral therapy in the treatment of hepatitis B cirrhosis with hepatic diabetes.Methods Fifty cases of patients with liver cirrhosis with hepatic diabetes in the hospital from January 2007 to October 2011 were randomly divided into two groups,bicyclol(75-150 mg/d,used 24weeks) combined ursodeoxycholic acid capsule(250 mg/d,used 24 weeks) used in 25 cases in control group,adefovir dipivoxil(10mg/d,used 24 weeks) was used in 25 cases in the observation group on the basis of that in control group,the indicators in patients were detected and comparativly analysed.Results The total effective and HBV-DNA negative cases in observation group were significantly better than control group,liver function ALT,AST,ALB and TBIL recovery situation in observation group were significantly better than control group,blood glucose target FPG and 2h PG in observation group were significantly better than control group,the difference was statistically significant(P < 0.05).Conclusion Clinical efficacy on antiviral therapy in the treatment of hepatitis B cirrhosis with hepatic diabetes is significant,it is a safe and effective treatment,worthy of clinical application.